首站-论文投稿智能助手
典型文献
"Elimination of Hepatitis by 2030" : Present Realities and Future Projections
文献摘要:
Each year, viral hepatitis and its complications affect millions of patients and cause one-and-a-half million deaths. To deal with this immense public health burden, international organizations have, as part of their sustainable development goals, set up the plan "Elimination of Hepatitis by 2030," which has been ratified by most countries. The plan’s aims include the prevention of different hepatitis viruses and the treatment of existing patients. However, a mid-term analysis revealed that lest novel maneuvers are adopted, some of the plan’s objectives may not be attained. While new infections seem to be contained by vaccines and other public health measures, the persistent reservoir of chronic hepatitis viruses -hepatitis B virus (HBV) and hepatitis C virus (HCV) - may not be properly addressed. Although antiviral therapy against chronic HCV infection is promising, chronic-HBV-infected persons may not be properly handled. There are about 296 million chronic hepatitis B (CHB) patients in the world, and only 10% of them are aware of their infection. Thus, the undetected CHB patients should be found, and a proper approach should be devised to address this issue, especially in developing countries that harbor the main bulk of CHB patients. In addition, there is no finite therapy for CHB patients, and the safety and efficacy of the existing drugs are also questionable. This indicates the need for novel drugs for CHB patients. In light of this, this study aimed to offer measures that could discover the millions of undetected patients and address the need for developing innovative drugs for CHB patients and thus substantiate the "Elimination of Hepatitis by 2030" plan.
文献关键词:
Hepatitis B virus;Elimination of Hepatitis by 2030;Innovative therapy;Prevention
作者姓名:
Akbar Sheikh Mohammad Fazle;AL-Mahtab Mamun;Khan Sakirul;Yoshida Osamu;Hiasa Yoichi
作者机构:
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan;Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, BSMMU, Dhaka 1000, Bangladesh;Department of Microbiology, Oita University, Oita, Japan
引用格式:
[1]Akbar Sheikh Mohammad Fazle;AL-Mahtab Mamun;Khan Sakirul;Yoshida Osamu;Hiasa Yoichi-."Elimination of Hepatitis by 2030" : Present Realities and Future Projections)[J].感染性疾病和免疫(英文),2022(01):3-8
A类:
Realities,lest,questionable
B类:
Elimination,Hepatitis,by,Present,Future,Projections,Each,year,hepatitis,its,complications,affect,millions,patients,cause,one,half,deaths,To,deal,this,immense,public,health,burden,international,organizations,have,part,their,sustainable,development,goals,set,up,plan,which,has,been,ratified,most,countries,aims,include,prevention,different,viruses,treatment,existing,However,mid,term,analysis,revealed,that,novel,maneuvers,adopted,some,objectives,may,not,attained,While,new,infections,seem,contained,vaccines,other,measures,persistent,reservoir,chronic,HBV,HCV,properly,addressed,Although,antiviral,therapy,against,promising,infected,persons,handled,There,about,CHB,world,only,them,aware,Thus,undetected,should,found,approach,devised,issue,especially,developing,harbor,main,bulk,addition,there,finite,safety,efficacy,drugs,also,This,indicates,need,light,study,aimed,offer,could,discover,innovative,thus,substantiate,Innovative,Prevention
AB值:
0.526965
相似文献
Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study
Jia Jingya;Zhu Qiuying;Deng Luojia;Lan Guanghua;Johnson Andrew;Chen Huanhuan;Shen Zhiyong;Li Jianjun;Xing Hui;Ruan Yuhua;Li Jing;Lu Hui;Vermund Sten H.;Zhu Jinhui;Qian Han-Zhu-SJTU-Yale Joint Center for Biostatistics and Data Science, Shanghai Jiao Tong University, Shanghai, China;Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China;Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China;Groton School, Groton, MA, USA;State Key Laboratory of Infectious Disease Prevention and Control (SKLID), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China;School of Public Health, Yale University, New Haven, CT, USA
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
Shen Junyi;Qi Weili;Dai Junlong;Leng Shusheng;Jiang Kangyi;Zhang Yu;Ran Shun;Li Chuan;Wen Tianfu-Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Laboratory of Liver Transplantation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610072, China;Department of Hepatobiliary and Pancreatic Surgery, The People's Hospital of Leshan, Leshan, Sichuan 614700, China;Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chinese Academy of Sciences, Chengdu, Sichuan 610072, China;Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000, China
A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients
Zheng Xiang;Zhang Weijie;Zhou Hua;Cao Ronghua;Shou Zhangfei;Zhang Shuwei;Cheng Ying;Chen Xuchun;Ding Chenguang;Tang Zuofu;Li Ning;Shi Shaohua;Zhou Qiang;Chen Qiuyuan;Chen Gang;Chen Zheng;Zhou Peijun;Hu Xiaopeng;Zhang Xiaodong;Na Ning;Wang Wei-Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing 100020, China;Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430032, China;Kidney Transplantation Dialysis Center, The Second People’s Hospital of Shanxi Province, Taiyuan, Shanxi 030012, China;Department of Organ Transplantation, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, China;Department of Nephrology, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang 310000, China;Department of Urology, Ningbo Yinzhou Number. 2 Hospital, Ningbo, Zhejiang 315000, China;Department of Organ Transplantation, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China;Institute of Kidney Transplantation, The First Affiliated Hospital, Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China;Department of Kidney, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China;Department of Kidney, Southwest Hospital, The First Hospital Affiliated to The Third Military Medical University (Army Medical University), Chongqing 400000, China;Organ Transplant Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China;Kidney Transplantation Center, Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, China
Deubiquitinase ubiquitin-specific protease 3 (USP3) inhibits HIV-1 replication via promoting APOBEC3G (A3G) expression in both enzyme activity-dependent and -independent manners
Zhao Simin;Zheng Baisong;Wang Liuli;Cui Wenzhe;Jiang Chunlai;Li Zhuo;Gao Wenying;Zhang Wenyan-Center for Pathogen Biology and Infectious Diseases, Institute of Virology and AIDS Research, Key Laboratory of Organ Regeneration and Transplantation of The Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin 130021, China;College of Life Science of Jilin University, Changchun, Jilin 130012, China;Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130012, China;Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin 130041, China;Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, China
Exercise for Cancer Therapy
Feng Min Zhang;Zhen Yu;Han Ping Shi;Ming Hua Cong;Hong Xia Xu;Cheng Le Zhuang-Department of Gastrointestinal Surgery,Shanghai Tenth People's Hospital Affiliated to Tongji University School of Medicine,Shanghai 200072,China;Department of Gastrointestinal Surgery/Department of Clinical Nutrition,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China;Key Laboratory of Cancer Food for Special Medical Purpose for State Market Regulation,Beijing 100038,China;Department of Comprehensive Care,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China;Department of Clinical Nutrition,Daping Hospital,Army Medical University(Third Military Medical University),Chongqing 400042,China;Colorectal Cancer Center,Shanghai Tenth People's Hospital Affiliated to Tongji University School of Medicine,Shanghai 200072,China
Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients
Minghui Li;Fangfang Sun;Xiaoyue Bi;Yanjie Lin;Liu Yang;Yao Lu;Lu Zhang;Gang Wan;Wei Yi;Linqing Zhao;Yao Xie-Department of Hepatology Division 2,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China;Department of Hepatology Division 2,Peking University Ditan Teaching Hospital,Beijing 100015,China;Department of Biostatistics,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China;Department of Gynecology and Obstetrics,Beijing Ditan Hospital,Capital Medical University,Beijing,100015,China;Laboratory of Virology,Beijing Key Laboratory of Etiology of Viral Diseases in Children,Capital Institute of Pediatrics,Beijing,100020,China
In vitro investigation of HBV clinical isolates from Chinese patients reveals that genotype C isolates possess higher infectivity than genotype B isolates
Tingting Liu;Anlei Liu;Yong Liu;Shan Cen;Quan Zhang-Department of Transfusion Medicine,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing,210008,China;Department of Emergency Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing,100730,China;Department of Laboratory Medicine,Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine,The Affiliated Hospital of Nanjing University Medical School,Nanjing,210008,China;Institute of Medicinal Biotechnology,Chinese Academy of Medical Science,Beijing,100050,China;Department of Infectious Diseases,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing,210008,China
Pathological Change of Chronic Hepatitis B Patients with Different Tongue Coatings by Circular Multi-omics Integrated Analysis
TANG Yi-shuang;GUO Jian-chun;XU Lin;ZHANG Xiao-na;SHEN Xiao-ping;HAI Ya-mei;MAO Yu-feng;HU Yi-yang;ZHAO Yu-Key Laboratory of Liver and Kidney Diseases,Institute of Liver Diseases,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203 ,China;Department of Integrated Chinese and Western Medicine,Hangzhou Xixi Hospital,Hangzhou 310023 ,China;National Engineering Center for Biochip at Shanghai,Shanghai 201203 ,China;Institute of Clinical Pharmacology,Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203 ,China;Shanghai Key Laboratory of Traditional Chinese Clinical Medicine,Shanghai 201203 ,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。